From Medscape Oncology

Coverage from the

European Society for Medical Oncology (ESMO) 2017 Congress

September 08 - 12, 2017; Madrid, Spain

September 08 - 12, 2017 Madrid, Spain

ESMO 'Buying a Ford but Paying for a Ferrari': Value in Cancer Care There is a fundamental lack of value in cancer care in which the cost of drugs is unrelated to their impact on clinical outcomes, says an expert who calls for changes in how treatments are assessed.
Medscape Medical News, October 12, 2017
ESMO Clear Benefit With Adjuvant Nivolumab in Resected Melanoma Adjuvant nivolumab significant improves relapse-free survival and reduces toxicity in comparison with ipilimumab in stage III/IV resected melanoma for patients at risk for relapse, trial results reveal.
Medscape Medical News, September 12, 2017
ESMO Chemoradiotherapy Remains Standard of Care in Cervical Cancer Chemoradiotherapy remains the standard of care for cervical cancer patients with locally advanced disease, concludes an Indian trial that compared it to neoadjuvant chemotherapy.
Medscape Medical News, September 11, 2017

Meeting Highlights At A Glance

Top News From ESMO 2017: Slideshow Practice-changing research in advanced renal cell carcinoma, adjuvant therapy for melanoma, and non-small cell lung cancer featured prominently at this year's congress.

Conference News

ESMO Lower-Dose Chemo Shows Promise in Second-line CRC
Medscape Medical News, November 28, 2017
ESMO 'Buying a Ford but Paying for a Ferrari': Value in Cancer Care
Medscape Medical News, October 12, 2017
ESMO Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data
Reuters Health Information, September 13, 2017
ESMO New Adjuvant Option for BRAF Melanoma
Medscape Medical News, September 12, 2017
ESMO Clear Benefit With Adjuvant Nivolumab in Resected Melanoma
Medscape Medical News, September 12, 2017
ESMO Hint of Survival Gain With Ramucirumab in Urothelial Cancer
Medscape Medical News, September 11, 2017
ESMO Cancer Patients Struggle to Understand Clinical Trials
Medscape Medical News, September 11, 2017
ESMO Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Medscape Medical News, September 11, 2017
ESMO Chemoradiotherapy Remains Standard of Care in Cervical Cancer
Medscape Medical News, September 11, 2017
ESMO Immunotherapy Changes First-Line Paradigm in Advanced RCC
Medscape Medical News, September 11, 2017

ESMO 'Spare Tire' Ups Cancer Risk More Than High BMI, Fat Percent
Medscape Medical News, September 10, 2017
ESMO Taselisib Added to Letrozole Boosts Response in Breast Cancer
Medscape Medical News, September 10, 2017
ESMO Durvalumab Boosts PFS Even in Stage 3 Lung Cancer
Medscape Medical News, September 9, 2017
ESMO Osimertinib Poised To Be New First-line Standard EGFRm NSCLC
Medscape Medical News, September 9, 2017
ESMO Novel Tool Identifies Palliative Care Needs Early in Cancer
Medscape Medical News, September 9, 2017
ESMO Alectinib Activity in CNS Metastases in Patients With ALK+ NSCLC
Medscape Medical News, September 8, 2017
ESMO MIRO: Minimally Invasive Surgery for Esophageal Cancer
Medscape Medical News, September 8, 2017
ESMO Ischemic Stroke May Hint at Underlying Cancer
Medscape Medical News, September 8, 2017
ESMO No Need for CT Scans in NSCLC Postsurgery Follow-up?
Medscape Medical News, September 1, 2017
ESMO What's Hot at ESMO 2017?
Medscape Medical News, August 29, 2017

Popular News from the ESMO 2016

Earthquake in Lung Cancer: Immunotherapy First-Line Pembrolizumab is set to become a new standard of care for first-line treatment of non-small cell lung cancer, but why did nivolumab fail?
Medscape Medical News, Oct 14, 2016
Left vs Right Difference in CRC: Now Practice Changing? More evidence for the prognostic and predictive value of primary tumor location or tumor 'sidedness' in metastatic colorectal CA could change clinical practice.
Medscape Medical News, Oct 12, 2016
Action on European Cancer Care Disparities 'Essential' A combination of ambitious targets and measurable outcomes will be needed if the stark disparities in cancer care and outcomes are to be tackled and reduced, say a group of leading experts.
Medscape Medical News, Oct 10, 2016

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Perspectives

Next Steps for Immunotherapies, Cell Therapies in Oncology
Stefan Zimmermann, MD; Inge Marie Svane, MD, PhD; George Coukos, MD, PhD
ESMO Data Clarify Differences in Pay, Mentorship, and Professional Opportunities for Women in Oncology
Solange Peters, MD, PhD; Eva Thalmann, PhD; Giuseppe Curigliano, MD, PhD
When to Stop Immunotherapy: First Response? Max Response? Toxicity?
Theodore Bosworth
Prostate Cancer Care Is 'Changing Rapidly': ESMO 2017
Johann S. de Bono, MD, PhD
Optimizing Treatment for Castration-Resistant Prostate Cancer
Liam Davenport
Stage III CRC: Which Patients Need 6 Months of Adjuvant Chemo?
Alberto Sobrero, MD; Julien Taieb, MD, PhD
New Techniques to Predict Response to Immunotherapy
Liam Davenport
Gut Microbiome May Be Key Variable in Immunotherapy Efficacy
Theodore Bosworth
ESMO's Practice-Changing Lung Cancer Data: Three Experts Discuss
H. Jack West, MD; Hossein Borghaei, DO, MS; Sanjay Popat, MBBS, PhD
'Important' Progress in Gynecologic Cancers: ESMO 2017
Susana Banerjee, MBBS, MA, PhD, FRCP
Adjuvant BRAF and MEK Inhibition for Melanoma: 'Impressive'
Jeffrey S. Weber, MD, PhD
Durvalumab After Chemoradiotherapy 'Immediately Changes Practice'
Mark G. Kris, MD
Liquid Biopsy Likely to Have 'Major Impact' in Breast Cancer
Theodore Bosworth
Colorectal Cancer Therapy Gets a Tune-up: ESMO 2017
David Kerr, CBE, MD, DSc, FRCP, FMedSci;
Dirk Arnold, MD, PhD
Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice
Floriana Morgillo, MD, PhD; H. Jack West, MD; Stefan Zimmermann, MD
Jack West, MD: Top Five Lung Cancer Abstracts at ESMO 2017
H. Jack West

Live Blog

News and Views from ESMO 2017 Coverage of key advances and expert reactions as they happened at the meeting.

Previous Coverage